Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.
17 patients with moderate to severe Raynaud's phenomenon were entered into a 6 week randomised double-blind crossover study to compare the efficacy of nifedipine with that of placebo. Nifedipine significantly reduced the frequency of attacks and also the severity of attacks, which was assessed by the patients on a linear analogue scale. Patients gave nifedipine a significantly higher drug-effectiveness score than placebo. Skin temperature recovery times were not affected by treatment with nifedipine. 12 of the patients regarded nifedipine as effective in reducing the frequency and severity of Raynaud's phenomenon.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D009543:Nifedipine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D011897:Random Allocation; D011928:Raynaud Disease / Q000188:drug therapy* / Q000209:etiology; D012881:Skin Temperature / Q000187:drug effects
D011725:Pyridines; D009543:Nifedipine